Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2026-01-14 00:00:00 ET · period of report 2026-01-12 · accession 0001665124-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-14 | 2026-01-12 | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $1.15 | +200.0K | 1.12M | +22% | +$229.6K |
| D | 2026-01-14 | 2026-01-12 | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale+OE | $4.71 | -200.0K | 1.01M | -17% | -$942.0K |
| D | 2026-01-14 | 2026-01-12 | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | A - Grant | $0.00 | +427.0K | 1.43M | +42% | $0 |
| DM | 2026-01-14 | 2026-01-12 | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $0.00 | -200.0K | 474.9K | -30% | $0 |
| D | 2026-01-14 | 2026-01-12 | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | A - Grant | $0.00 | +274.0K | 274.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-12 | M | A | 88,676 | $1.71 | 1,206,439 | D | — | — | |
| 2 | Common | Common Stock | 2026-01-12 | M | A | 111,324 | $0.7 | 1,117,763 | D | — | — | |
| 3 | Common | Common Stock | 2026-01-12 | S | D | 200,000 | $4.71 | 1,006,439 | D | — | — | (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-01-12 | A | A | 427,000 | $0.00 | 1,433,439 | D | — | — | (F3) Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date. |
| 5 | Derivative | Employee Stock Option (right to buy) | 2026-01-12 | M | D | 111,324 | $0.00 | 111,359 | D | $0.7 · — to 2033-12-14 | 111,324 Common Stock | (F4) The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. |
| 6 | Derivative | Employee Stock Option (right to buy) | 2026-01-12 | M | D | 88,676 | $0.00 | 474,941 | D | $1.71 · — to 2034-01-02 | 88,676 Common Stock | (F5) 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
| 7 | Derivative | Employee Stock Option (right to buy) | 2026-01-12 | A | A | 274,000 | $0.00 | 274,000 | D | $4.86 · — to 2036-01-12 | 274,000 Common Stock | (F6) 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |